STOCK TITAN

FSD Pharma Inc. - $HUGE STOCK NEWS

Welcome to our dedicated page for FSD Pharma news (Ticker: $HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma's position in the market.

Rhea-AI Summary

FSD Pharma has submitted a clinical trial protocol for Unbuzzd™, aimed at studying its safety and efficacy in treating acute alcohol intoxication. The METAL-2 trial will be conducted with healthy volunteers in a crossover design. The protocol is awaiting approval from an institutional review board (IRB) in the USA. Recruitment for the trial will commence once approval is granted. Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at FSD Pharma, expressed enthusiasm about reaching this milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
News
Rhea-AI Summary

On May 24, 2024, FSD Pharma announced an investor relations services agreement with IR Agency, starting on May 22, 2024. The agreement aims to enhance communication with the financial community through creating company profiles, media distribution, and building a digital community. The service will last one month and cost C$335,699 (approximately US$245,000). The IR Agency, led by Rafael Pereira, is independent of FSD Pharma and holds no equity interest in the company's securities. The agency will work from May 28, 2024, to June 28, 2024, to help the company achieve its communication goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary

On May 16, 2024, FSD Pharma and Celly Nutrition announced new packaging and logo for their beverage product, unbuzzd™. The product, designed to aid in alcohol metabolism and promote alertness, will launch this summer. The new design, developed with Six+One, features a vibrant green and yellow color scheme and a playful logo to appeal to a broad demographic. The packaging will be available in various formats, emphasizing the product's scientific development and benefits. Unbuzzd™ aims to balance fun with responsibility, promoting safe and mindful consumption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
Rhea-AI Summary

FSD Pharma, a biopharmaceutical company, has submitted a Phase-1 clinical trial application for Lucid-21-302 in Australia. Lucid-21-302 is a neuroprotective compound for the treatment of multiple sclerosis, showing promise in preclinical models. The company aims to advance Lucid-21-302 into a phase-2 clinical trial, with optimism about its potential as a treatment for MS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
Rhea-AI Summary

FSD Pharma signed an agreement with Applied Science and Performance Institute (ASPI) to conduct a clinical trial in the United States to assess the safety and efficacy of unbuzzd(TM) in an induced state of alcohol intoxication. The trial will compare the effects of unbuzzd(TM) to a placebo in thirty healthy volunteers. FSD Pharma aims to establish itself as a leader in products targeting alcohol intoxication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
-
Rhea-AI Summary
FSD Pharma provides an update on Celly Nu's partnership with Six+One for unbuzzd(TM), a new innovative beverage product designed to support the body's natural processes. Celly Nu announced a strategic partnership with Six+One to enhance the presence of unbuzzd(TM) in the US market, leveraging Six+One's branding expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
partnership
Rhea-AI Summary
FSD Pharma provides an update on Celly Nu's anticipated launch of unbuzzd(TM), a scientifically formulated beverage product designed to support alcohol metabolism and alertness. Celly Nu partners with BevSource for production and distribution in the US. The partnership includes various services to ensure a successful launch. The product, unbuzzd(TM), features a blend of vitamins, minerals, and botanical extracts. Industry veterans like Gerry David and John Duffy lead the project, supported by Kevin Harrington.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
Rhea-AI Summary
FSD Pharma, a biopharmaceutical company, expands its pipeline to include potential weight loss and liver health formulations and products. The company is investigating ingredients and dietary supplements to promote weight loss, liver health, and faster alcohol metabolism. This move aims to address metabolic disorders and create a new product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
-
Rhea-AI Summary
FSD Pharma increases investment in Celly Nutrition Corp. to launch a product expediting alcohol metabolism and recovery. The loan agreement allows for the principal increase by $300,000, deferral of interest payments, and potential conversion to common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.4%
Tags
none
Rhea-AI Summary
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
FSD Pharma Inc.

Nasdaq:HUGE

HUGE Rankings

HUGE Stock Data

14.53M
34.34M
17.37%
2.53%
0.82%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Toronto

About HUGE

fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.